Table 4.

 Adverse event summary

	Fixed combination latanoprost/timolol (n = 165)		Unfixed combination brimonidine/timolol (n = 167)
	n	%	n	%
No adverse event	126	76.4	126	75.5
At least one adverse event	39	23.6	41	24.6
Ocular adverse event(s)	29	17.6	34	20.4
Systemic adverse event(s)	14	8.5	13	7.8
Adverse event(s) related to study medication	12	7.3	31	18.6
Discontinuation due to adverse event(s)	3	1.8	18	10.8
Serious adverse event(s)	4	2.4	1	0.6